Home›Trial›NCT03154697
NCT03154697RECRUITING

Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances

Study Summary

This database will be used to better understand the sleep problems of people with SMS. This clinical database will be a part of a larger Smith-Magenis Patient Registry used to create an awareness campaign around SMS and the sleep disturbances that are characteristic of the disorder.

Conditions
Sleep Disturbances in Smith-Magenis Syndrome
Interventions / Drugs
Data collection of sleep disturbances in individuals with SMS
View on ClinicalTrials.gov ↗
Sponsor
VNDA
Vanda Pharmaceuticals
Neuroscience
D41/100
Study Details
Enrollment1000 participants
Primary Completion—
Lead SponsorVanda Pharmaceuticals
Data Retrieved2026-04-11 04:31:05.188650+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 1,000 participants
Sponsor Catalyst Profile

Vanda Pharmaceuticals (VNDA) is the sponsoring company for this trial. BiotechSign currently grades this company D (41/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

VNDA Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.